Group therapy program for managing voices in people with schizophrenia
Tests a group therapy program for voices that medicine has not eased in schizophrenia.
Plain-language title generated from the registry record
Registry title: Validation of a VOICE MAnagement Program in Schizophrenia VVoice MAPS
Key facts
- Where
- Les Abymes, GuadeloupeSee the site
Where in Guadeloupe
- Public Mental Health Institution of GuadeloupeLes Abymes, GuadeloupeNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de la Guadeloupe
- Trial code
- NCT07266376
- Record updated
- 5 December 2025
- Original description
Approximately 25-50% of patients with schizophrenia experience treatment-resistant Auditory Verbal Hallucinations (AVHs), which contribute to the development of associated psychopathological disorders (e.g., anxiety, depression, suicidal ideation). Various validated psychotherapeutic strategies and tools for managing treatment-resistant AVHs have been combined into an integrative therapeutic program. The main objective of this study is to evaluate the efficacy of this program in reducing the frequency and intensity of AVHs, as well as its impact on comorbid psychopathology (e.g., depression, anxiety, self-esteem, substance use) in patients with schizophrenia or schizoaffective disorder who experience treatment-resistant AVHs.Read full original descriptionShow less
Validation of a VOICE MAnagement Program in Schizophrenia
Approximately 25-50% of patients with schizophrenia experience treatment-resistant Auditory Verbal Hallucinations (AVHs), which contribute to the development of associated psychopathological disorders (e.g., anxiety, depression, suicidal ideation). Various validated psychotherapeutic strategies and tools for managing treatment-resistant AVHs have been combined into an integrative therapeutic program. The main objective of this study is to evaluate the efficacy of this program in reducing the frequency and intensity of AVHs, as well as its impact on comorbid psychopathology (e.g., depression, anxiety, self-esteem, substance use) in patients with schizophrenia or schizoaffective disorder who experience treatment-resistant AVHs.
Inclusion: Consenting patients over 18 years of age will be enrolled in the study if they meet all of the following criteria:; Diagnosis: Fulfill DSM-5 criteria for schizophrenia or schizoaffective disorder; Resistant AVHs: Present treatment-resistant auditory verbal hallucinations (AVHs), defined as the persistence of daily hallucinations without remission despite adequate antipsychotic medication for at least 3 months; Motivation: Express a request for relief from voices; Treatment Setting: Are outpatients being treated in psychiatric departments at the Public Mental Health Institution of Guadeloupe or the University Hospital Center of Nîmes; Severity: Have a score of greater than 9 on the Psychotic Symptom Rating Scale - Auditory Hallucinations subscale (PSYRATS-AH).
Exclusion: Participation in another study: Currently taking part in another clinical trial or within the exclusion period of another study; Inability to provide informed consent: Failure or impossibility to provide the patient with sufficient information to allow an informed decision; Severe substance abuse: Presence of severe substance use disorder; Acute somatic decompensation: Experiencing an acute medical condition that may compromise participation in the study; Patients will be excluded from the study if they meet any of the following criteria:; Consent refusal: Refuse to sign the written informed consent.